INTRODUCTION {#sec1-1}
============

Functional dyspepsia (FD) is a prevalent gastrointestinal (GI) disorder. Its prevalence is different in various populations and outpatient clinics.\[[@ref1]\] The patients suffer from dyspepsia, but no pathologic lesion, or metabolic abnormality is identified.\[[@ref2]\] They complain about epigastric pain/burning or upper abdomen postprandial discomforts. According to Rome III criteria, FD includes two main subtypes of epigastric pain syndrome and postprandial distress syndrome (PDS).\[[@ref3][@ref4]\] The latter involves patients with meal-related symptoms of bothersome postprandial fullness and early satiety. Its etiology is very complex and may include gastric dysmotility (delayed gastric emptying),\[[@ref5][@ref6][@ref7]\] *Helicobacter pylori* infection,\[[@ref8][@ref9][@ref10][@ref11][@ref12]\] local inflammations,\[[@ref2][@ref13][@ref14][@ref15][@ref16][@ref17]\] abnormal brain-gut interactions,\[[@ref18][@ref19][@ref20][@ref21][@ref22][@ref23][@ref24][@ref25][@ref26]\] abnormal acid secretion,\[[@ref27][@ref28]\] genetic susceptibility,\[[@ref29][@ref30][@ref31]\] imbalanced autonomic nervous system and visceral hypersensitivity.\[[@ref32][@ref33][@ref34][@ref35][@ref36][@ref37]\] Although the regular pharmacologic treatments for FD include antacids, kinetic-modifying agents, anti-*H. pylori* antibiotics, anxiolytics, and antidepressants, their benefits are limited in many cases and remained unsatisfactory.\[[@ref38][@ref39]\] That\'s why the search for optimum treatment is continued, and alternative medicine has gained more and more popularity among the patients and even physicians. It has been estimated by World Health Organization that probably 80% of the population around the world may trust traditional medicine to meet their primary health care needs.\[[@ref40]\] Unfortunately, there isn't enough satisfactory evidence based on randomized clinical trials to demonstrate the efficacy and safety of the majority of herbal medicines. One of the herbs in the latter group used to treat patients in over 4000-year history of Iranian medicine was *Pimpinella anisum* (Apiaceae).\[[@ref41]\] Different therapeutic effects have been reported for anise including antioxidant, antifungal,\[[@ref42]\] antimicrobial,\[[@ref43]\] analgesic,\[[@ref44]\] anticonvulsant\[[@ref45][@ref46]\] and antispastic\[[@ref47]\] properties. It also has many GI effects. For instance, anise implemented its antiulcer effects by inhibiting gastric mucosal damage.\[[@ref48]\] The aromatic effects of anise have been effective in the palliation of nausea.\[[@ref49]\] Its laxative property has been effective in the treatment of constipation.\[[@ref50]\] The aim of current clinical trial was to assess the effects of anise fruit on patients with PDS.

MATERIALS AND METHODS {#sec1-2}
=====================

Study design {#sec2-1}
------------

The current study was a double-blind, randomized clinical trial conducted in Isfahan University of Medical Sciences (IUMS). Patients attending Gastroenterology Clinic of the university hospital from August 2013 to March 2014 were evaluated. Totally, 180 patients were visited and assessed. Those who fulfilled the inclusion criteria and signed a written consent form were enrolled in the study. The research protocol was approved by Ethical Committee. The study was registered in Iranian Registry of Clinical Trials (registration number, 2013101214980). Inclusion criteria were age of 18-65 years and diagnosed with PDS according to ROME III criteria. The patients had at least one of the following symptoms occurring several times a week in the past 6 months: The discomfort feeling of postprandial fullness and/or early satiety. Exclusion criteria included pregnancy, breastfeeding, peptic ulcer, gastroesophageal reflux disease, dysphagia, celiac, GI surgery, irritable bowel syndrome, abdominal pain, night diarrhea, greasy or black stool, blood in stool, mental retardation, immune system disorders, major depression, bipolar disorder and psychosomatic disorders, severe recent weight loss, cancer, renal disorders, current use of antibiotics, proton pump inhibitors, H2 blockers, bismuth, metoclopramide, domperidone, lactulose, nonsteroid anti-inflammatory drugs, corticosteroids, herbal medicines and drug abuse. Patients who took \<80% of administered medication or had drug intolerance were withdrawn from the study.

Subjects and intervention {#sec2-2}
-------------------------

Totally, 107 patients were enrolled in the study \[[Figure 1](#F1){ref-type="fig"}\]. They were randomized by simple randomization method to blindly receive either anise or placebo for 4 weeks. Intervention group consisted of 47 patients and received anise powder, 3 gafter each meal (3 times/day). According to the Barnes *et al*.,\[[@ref51]\] administration of up to 20 g/day anise powder is safe. The anise seeds were prepared by Barij Essence Pharmaceutical Company (MashhadArdehal, Iran) as a gift. This plant specimen was kept in their herbarium with number 1697.\[[@ref52]\] Control group included 60 patients and received placebo powder, 3 g after each meal (3 times/day). The latter included corn starch and were similar to anise package in shape, color, and size. Both powders were prepared in similar packages by Pharmacognosy Department of Isfahan School of Pharmacy at IUMS. One week medications were supplied to the patients at the beginning of the each week for 4 weeks. Both patients and doctors were blind to the treatments.

![Consort flowchart of the study](JRMS-20-13-g001){#F1}

Instruments and outcomes {#sec2-3}
------------------------

To evaluate the presence or absence of symptoms of FD, modified ROME III questionnaire,\[[@ref3][@ref53]\] was used. Its validity and reliability have been tested before.\[[@ref54]\] The diagnosis of FD was based on the questionnaire filled out individually. To assess the severity of the disorder, FD severity scale was employed.\[[@ref55]\] 4-item Likert scale (never or rarely, not very unpleasant, very unpleasant but tolerable, and can't tolerate) was employed to answer the questions. Each participant\'s total score was between 0 and 48. A detailed questionnaire was prepared to record the medication side effects too.

All patients were followed-up for 12 weeks. The primary and secondary endpoints were the mean score of severity of FD and the frequency distribution of patients with various severities across the study period, respectively. Assessments were carried out at baseline and at the end of weeks 2, 4 and 12.

Statistical analysis {#sec2-4}
--------------------

Intention to treat analysis was used to avoid the bias associated with nonrandom loss of patients. Characteristics of the two groups were compared before and after intervention using Mann-Whitney U and Kruskal-Wallis tests for nonparametric variables and Student\'s *t*-test for parametric variables. The changes from the baseline to the end of study period within each group were tested using Friedman test and related samples Friedman\'s two-way analysis of variance by ranks test. *P* \< 0.05 were considered significant. Statistical Package for Social Sciences (SPSS Inc., Chicago, IL, USA), version 17 for Windows was used to conduct statistical analysis.

RESULTS {#sec1-3}
=======

Totally, 107 patients were enrolled in the study. Totally, 32 (53.3%) and 21 (44.7%) females were included in the control and intervention groups, respectively. The difference was not significant (*P* = 0.3). The mean (standard deviation \[SD\]) age of patients in the control group was 41 (11.7) and in the intervention group was 45.5 (15.5) years (*P* = 0.1). Totally, 34 (56.7%) and 32 (68%) patients had body mass index ≤25 in the control and intervention groups, respectively (*P* = 0.4). Totally, 47 (78.3%) patients in the control group and 36 (76.6%) patients in the intervention group never smoked cigarettes (*P* = 0.9). Totally, 58 (96.7%) and 43 (91%) patients didn't drink coffee in the control and intervention groups, respectively (*P* = 0.1). Four patients were withdrawn from the study in each group \[[Figure 1](#F1){ref-type="fig"}\]. No serious medication side effect was reported in anise group.

Mean (SD) scores of 16 questions of FD severity scale in the two groups across the study period are shown in [Table 1](#T1){ref-type="table"}. Among all symptoms, epigastric fullness showed the highest severity and nausea demonstrated the lowest severity in both groups before the intervention \[[Table 1](#T1){ref-type="table"}\]. In other words, about 90% of patients had epigastric fullness whereas ≤5% suffered from nausea in both groups at baseline. The baseline mean scores of different FD symptoms were not significantly different between the two groups. After intervention, all symptoms were significantly different between the two groups at weeks 4 and 12, but retching, nausea and vomiting. Similarly, mean total scores of FD severity scale were not significantly different between the two groups before the intervention. But, they were significantly different between the two groups at weeks 2, 4 and 12 \[[Table 1](#T1){ref-type="table"}\].

###### 

Comparison of mean (SD) scores of severity of FD within and between the two groups across the study period

![](JRMS-20-13-g002)

Mean severity scores of epigastric fullness, epigastric discomfort, epigastric burning/pain, early satiety, bloating, belching, and loss of appetite decreased significantly within anise group after intervention whereas only epigastric discomfort showed similar pattern within placebo group. On the other hand, mean severity scores of epigastric pain, epigastric fullness and belching increased significantly within the placebo group after intervention whereas no symptom revealed such an increasing score pattern within anise group \[[Table 1](#T1){ref-type="table"}\].

Distributions of the patients in different scales of severity of FD symptoms across the study period are demonstrated in [Table 2](#T2){ref-type="table"}. Similar to the mean severity scores, the distributions of patients before intervention were not significantly different between the two groups \[[Table 2](#T2){ref-type="table"}\]. Furthermore, the patterns of significance and nonsignificance of distributions of patients within each group and between the two groups were similar to those of the severity scores.

###### 

Distributions of the patients according to various degrees of severity of FD and comparison of distributions within and between the two groups across the study period

![](JRMS-20-13-g003)

DISCUSSION {#sec1-4}
==========

The current study demonstrated that anise was effective in the treatment of postpartum depression (PPD). Since the pathophysiology of FD is multifactorial and since anise has broad spectrum of pharmacological effects on GI, nervous, muscular and immune systems, it is not a surprise to see significant improvements of symptoms in patients with FD. The spasmolytic feature\[[@ref50]\] of anise and its pain relieving character may explain the improvement of postprandial pain and epigastric discomfort. Antimicrobial effects\[[@ref43]\] of anise against most bacteria may decrease or inhibit the activities of *H. pylori* in these patients. Inhibitory effects of anise on gastric mucosal damage\[[@ref48]\] may decrease the micro-inflammation of FD. The most important constituents of aniseeds essential oils responsible for the reported effects are trans-anethole, estragole, γ-hymachalen, p-anisaldehyde, and methyl chavicol.\[[@ref56]\]

Some other herbs have also been investigated to find out their effectiveness on FD treatment with various results. The most famous ones were Iberogas (a herbal combination preparation, STW 5) which improved the symptoms of FD in 52-68% of cases and peppermint which was effective in 67-97% of patients.\[[@ref57]\] Some of them have also been recognized to relieve bloating and intestinal gas. They are called carminatives. Anise, peppermint, and cinnamon are the prototypes of these herbs but few clinical trials have been carried out to show the evidence.\[[@ref58]\] This was the first randomized clinical trial assessing the therapeutic effects of anise on patients with FD. But, this study had the following limitations. First, it was conducted in a single center. Thus, the study population was homogenous which limited the external validity of the results. Second, the sample size was small, and the follow-up period was relatively short. It is suggested to include larger numbers of patients with longer periods of follow-up in multiple centers in the future investigations.

CONCLUSIONS {#sec1-5}
===========

Anise was effective and tolerable in the relieving the symptoms of PPD. These effects were observed even 8 weeks after discontinuation of anise administration.
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